See more : Aladdin Healthcare Technologies SE (ALDNF) Income Statement Analysis – Financial Results
Complete financial analysis of Protara Therapeutics, Inc. (TARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Spire Inc. (SR) Income Statement Analysis – Financial Results
- Next Meats Holdings, Inc. (NXMH) Income Statement Analysis – Financial Results
- Oceana Lithium Limited (OCN.AX) Income Statement Analysis – Financial Results
- Aurora Solar Technologies Inc. (AACTF) Income Statement Analysis – Financial Results
- NUGL Inc. (NUGL) Income Statement Analysis – Financial Results
Protara Therapeutics, Inc. (TARA)
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.95M | 0.00 | 0.00 |
| Cost of Revenue | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 0.00 | 27.00K | 57.00K |
| Gross Profit | -341.00K | -247.00K | -1.17M | -196.00K | -16.00K | -115.00K | -148.00K | -123.00K | -57.00K | 2.95M | -27.00K | -57.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.99M | 16.81M | 21.09M | 11.98M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
| General & Administrative | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 105.99K | 9.84M | 8.49M | 4.10M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.42M | -123.00K | -57.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.10M | 3.10M | 2.03M |
| Other Expenses | 0.00 | 29.52M | 0.00 | 0.00 | 0.00 | 207.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.10M | 7.94M |
| Cost & Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.36M | 28.71M | 20.87M | 10.53M | 7.12M | 8.00M |
| Interest Income | 2.73M | 1.11M | 237.00K | 466.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 20.00K |
| Interest Expense | 0.00 | 1.14M | 1.74M | 34.00K | 0.00 | 0.00 | 259.00K | 193.00K | 144.00K | 857.00K | 861.00K | 0.00 |
| Depreciation & Amortization | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 30.00K | 27.00K | 57.00K |
| EBITDA | -43.27M | -64.57M | -46.09M | -33.78M | -7.81M | -20.61M | -29.82M | -28.40M | -21.32M | -2.45M | -7.02M | -7.91M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -83.28% | 0.00% | 0.00% |
| Operating Income | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.71M | -20.87M | -7.58M | -7.12M | -8.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -257.12% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.19M | 1.11M | 237.00K | 466.00K | 0.00 | 643.00K | 398.00K | 179.00K | -507.00K | 4.24M | -790.00K | 26.00K |
| Income Before Tax | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -117.00K | -466.00K | -262.00K | 5.35M | 657.00K | 372.00K | -363.00K | 5.10M | 0.00 | 0.00 |
| Net Income | -40.42M | -64.82M | -47.14M | -33.51M | -14.73M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -113.36% | 0.00% | 0.00% |
| EPS | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| EPS Diluted | -3.57 | -5.76 | -4.20 | -4.63 | -228.60 | -9.93 | -69.38 | -68.90 | -51.94 | -43.62 | -37.43 | -37.62 |
| Weighted Avg Shares Out | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
| Weighted Avg Shares Out (Dil) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:
Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright...
TARA Stock: Why The Price Increased This Past Week
The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.
Biopharma Stock Skyrockets on FDA Approval
Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.
Why Protara Therapeutics Stock Is Rising Today
Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer. Protara Therapeutics expects to begin a Phase 1 clinical trial of...
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End -
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall...
New Strong Sell Stocks for June 29th
ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.
2 Falling Knives to Catch
Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performance over the prior 52 weeks through June 3....
TARA Stock: Over 7% Decrease Pre-Market Explanation
The stock price of Protara Therapeutics Inc (NASDAQ: TARA) fell by over 7% pre-market. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports